Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Published:2023-04-20 Issue:16 Volume:388 Page:1478-1490
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Hoeper Marius M.¹^ORCID,Badesch David B.¹,Ghofrani H. Ardeschir¹,Gibbs J. Simon R.¹,Gomberg-Maitland Mardi¹,McLaughlin Vallerie V.¹,Preston Ioana R.¹^ORCID,Souza Rogerio¹^ORCID,Waxman Aaron B.¹,Grünig Ekkehard¹,Kopeć Grzegorz¹,Meyer Gisela¹,Olsson Karen M.¹,Rosenkranz Stephan¹,Xu Yayun¹,Miller Barry¹,Fowler Marcie¹,Butler John¹,Koglin Joerg¹,de Oliveira Pena Janethe¹,Humbert Marc¹

Affiliation:

1. From the Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Member of the German Center for Lung Research, Biomedical Research in End-Stage and Obstructive Lung Disease Hannover, Hannover (M.M.H., K.M.O.), the Department of Internal Medicine, Universities of Giessen and Marburg Lung Center, Institute for Lung Health, Cardio-Pulmonary Institute, Member of the German Center for Lung Research, Giessen (H.A.G.), Thoraxklinik-Heidelberg and the German Center for Lung Research...

Funder

Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2213558

Reference21 articles.

1. Pulmonary Arterial Hypertension

2. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

3. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension